Get the paper from Cancer Chemotherapy and Pharmacology here
TAS-102 was approved in America in 2015 as Lonsurf®.
Retrieve the paper from here
This white paper describes why LC or LC-MS/MS methods must be carefully evaluated as they are adopted for LC+AMS use and why the resultant LC+AMS method must be fully validated before use. A three-batch validation is the only way to ensure method reproducibility and deliver LC+AMS data reliably.
Presented at the 21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds, International Isotope Society-Central European Division, Bad Soden, Germany
Download the presentation from here
Successful Clinical [14C] Microtracer Investigations – Case Studies from GSK and Genentech
Thursday, 24th September 2015 at 11:00 am EDT – 12:00 pm EDT
Go here to pre-register for the webinar
Stephen English – “The successful application of carbon isotopes in preclinical and clinical pharmaceutical research”
Friday, 2nd October 2015
International Isotope Society-Central European Division
21st Workshop on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds
Bad Soden, Germany
Surveying the Boundaries of Accelerator Mass Spectrometry: The Widening Scope of an Evolving Technology
Read the presentation
Go here to download speaker presentations, listen to and watch a recording of the presentations or read our comprehensive Q&A
Our concise two-pager was written by our AMS engineer Eric Guarin
Download How AMS Detection Works
Taiho prodrug TAS-102 – PK, excretory pathways and metabolism determined in patients with advanced solid tumors using HPLC plus AMS
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.